ESMO Colloquium
Date
22.09.2020
Chairs
  • Alexander Drilon (New York, NY, United States of America)
  • Giuseppe Curigliano (Milan, Italy)
ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium
ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

Introduction to RET mutations and fusions and their incidence for potential use as target in cancer treatment

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

RET fusion TKI: Present results and recent developments in Lung cancer

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

RET alterations in Thyroid carcinomas: Results and recent update

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

RET determination: Present recommendation of the ESMO Precision Medicine working group

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

Conclusion: Is RET targeting ready for an agnostic use?

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment ESMO Colloquium

Live Q&A

Speakers
  • Giuseppe Curigliano (Milan, Italy)
  • Alexander Drilon (New York, NY, United States of America)